Colorectal cancer, diabetes and survival: Epidemiological insights

Diabetes and Metabolism

Volumn 40, Issue 2, 2014, Pages 120-127

  Zanders, M M J ^a   Vissers, P A J ^a,b   Haak, H R ^c   Van de Poll Franse, L V ^a,b  

^a Eindhoven Cancer Registry   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Diabetes; Overall survival; Review

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

AGE; BODY MASS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; DIABETES CONTROL; DIABETES MELLITUS; HUMAN; LIFESTYLE; MORTALITY; OVERALL SURVIVAL; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE; AGE DISTRIBUTION; COLORECTAL TUMOR; COMPLICATION; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PROGNOSIS; SURVIVAL; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; AGE DISTRIBUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84899113879     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.12.007     Document Type: Review

References (77)

1. Jiang Y., Ben Q., Shen H., Lu W., Zhang Y., Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011, 26:863-876.
2. Kramer H.U., Schottker B., Raum E. Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer 2012, 48:1269-1282.
3. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
4. Deng L., Gui Z., Zhao L., Wang J., Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012, 57:1576-1585.
5. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008, 300:2754-2764.
6. Jullumstro E., Kollind M., Lydersen S., Edna T.H. Diabetes mellitus and outcomes of colorectal cancer. Acta Oncol 2009, 48:361-367.
7. Meyerhardt J.A., Catalano P.J., Haller D.G., Mayer R.J., Macdonald J.S., Benson A.B., et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003, 21:433-440.
8. Stein K.B., Snyder C.F., Barone B.B., Yeh H.C., Peairs K.S., Derr R.L., et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci 2010, 55:1839-1851.
9. van de Poll-Franse L.V., Haak H.R., Coebergh J.W., Janssen-Heijnen M.L., Lemmens V.E. Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia 2012, 55:2163-2172.
10. Dehal A.N., Newton C.C., Jacobs E.J., Patel A.V., Gapstur S.M., Campbell P.T. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2011, 30:53-59.
11. Polednak A.P. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer Detect Prev 2006, 30:466-472.
12. van de Poll-Franse L.V., Houterman S., Janssen-Heijnen M.L., Dercksen M.W., Coebergh J.W., Haak H.R. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer 2007, 120:1986-1992.
13. Bella F., Minicozzi P., Giacomin A., Crocetti E., Federico M., Ponz de Leon M., et al. Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. J Cancer Res Clin Oncol 2013, 139:1303-1310.
14. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010, 60:207-221.
15. Jeon J.Y., Jeong D.H., Park M.G., Lee J.W., Chu S.H., Park J.H., et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs rectal cancer. PLoS One 2013, 8:e55196.
16. Huang Y.C., Lin J.K., Chen W.S., Lin T.C., Yang S.H., Jiang J.K., et al. Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease. J Cancer Res Clin Oncol 2011, 137:211-220.
17. van Waalwijk M.A., van de Schans S.A.M., Haak H.R., Extermann M., Dercksen M.W., Janssen-Heijnen M. Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer. J Comorbidity 2011, 1:19-27.
18. Renehan A.G., Yeh H.C., Johnson J.A., Wild S.H., Gale E.A., Moller H. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012, 55:1619-1632.
19. Koller M.T., Raatz H., Steyerberg E.W., Wolbers M. Competing risks and the clinical community: irrelevance or ignorance. Stat Med 2011, 31:1089-1097.
20. Wolbers M., Koller M.T., Witteman J.C., Steyerberg E.W. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 2009, 20:555-561.
21. Flanders W.D. Inaccuracies of death certificate information. Epidemiology 1992, 3:3-5.
22. Hinchliffe S.R., Abrams K.R., Lambert P.C. The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol 2013, 37:11-19.
23. Richardson L.C., Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005, 2:48-53.
24. Sullivan P.W., Morrato E.H., Ghushchyan V., Wyatt H.R., Hill J.O. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000-2002. Diabetes Care 2005, 28:1599-1603.
25. Nivel LINH-Registration General Practitioners 2013, Available at http://www.nivel.nl/incidentie-en-prevalentiecijfers-in-de-huisartsenpraktijk. Last accessed 12 August.
26. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
27. Zanders M.M., van Steenbergen L.N., Haak H.R., Rutten H.J., Pruijt J.F., Poortmans P.M., et al. Diminishing differences in treatment between patients with colorectal cancer with and without diabetes: a population-based study. Diabet Med 2013, 30:1181-1188.
28. Johnson J.A., Carstensen B., Witte D., Bowker S.L., Lipscombe L., Renehan A.G. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012, 55:1607-1618.
29. Haire-Joshu D., Glasgow R.E., Tibbs T.L. Smoking and diabetes. Diabetes Care 1999, 22:1887-1898.
30. Romaguera D., Guevara M., Norat T., Langenberg C., Forouhi N.G., Sharp S., et al. Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project. Diabetes Care 2011, 34:1913-1918.
31. Meyerhardt J.A., Niedzwiecki D., Hollis D., Saltz L.B., Hu F.B., Mayer R.J., et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007, 298:754-764.
32. Pollak M. Do cancer cells care if their host is hungry?. Cell Metab 2009, 9:401-403.
33. Cichosz S.L., Fleischer J., Hoeyem P., Laugesen E., Poulsen P.L., Christiansen J.S., et al. Objective measurements of activity patterns in people with newly diagnosed type 2 diabetes demonstrate a sedentary lifestyle. Diabet Med 2013, 30:1063-1066.
34. Schienkiewitz A., Schulze M.B., Hoffmann K., Kroke A., Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006, 84:427-433.
35. Campbell P.T., Newton C.C., Dehal A.N., Jacobs E.J., Patel A.V., Gapstur S.M. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012, 30:42-52.
36. Denost Q., Quintane L., Buscail E., Martenot M., Laurent C., Rullier E. Short- and long-term impact of body mass index on laparoscopic rectal cancer surgery. Colorectal Dis 2012, 15:463-469.
37. Je Y., Jeon J.Y., Giovannucci E.L., Meyerhardt J.A. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer 2013, 133:1905-1913.
38. Meyerhardt J.A., Heseltine D., Niedzwiecki D., Hollis D., Saltz L.B., Mayer R.J., et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006, 24:3535-3541.
39. Baade P.D., Meng X., Youl P.H., Aitken J.F., Dunn J., Chambers S.K. The impact of body mass index and physical activity on mortality among patients with colorectal cancer in Queensland, Australia. Cancer Epidemiol Biomarkers Prev 2011, 20:1410-1420.
40. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
41. Fazio L., Cotterchio M., Manno M., McLaughlin J., Gallinger S. Association between colonic screening, subject characteristics, and stage of colorectal cancer. Am J Gastroenterol 2005, 100:2531-2539.
42. De Marco M.F., Janssen-Heijnen M.L., van der Heijden L.H., Coebergh J.W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000, 36:95-99.
43. Corkum M., Urquhart R., Kendell C., Burge F., Porter G., Johnston G. Impact of comorbidity and healthcare utilization on colorectal cancer stage at diagnosis: literature review. Cancer Causes Control 2012, 23:213-220.
44. Macleod U., Mitchell E.D., Burgess C., Macdonald S., Ramirez A.J. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer 2009, 101(Suppl.2):S92-S101.
45. Mitchell E., Macdonald S., Campbell N.C., Weller D., Macleod U. Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer 2008, 98:60-70.
46. Johnson J.A., Bowker S.L., Richardson K., Marra C.A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011, 54:2263-2271.
47. Lemmens V., van Steenbergen L., Janssen-Heijnen M., Martijn H., Rutten H., Coebergh J.W. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010, 49:784-796.
48. Limburg P.J., Anderson K.E., Johnson T.W., Jacobs D.R., Lazovich D., Hong C.P., et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005, 14:133-137.
49. He J., Stram D.O., Kolonel L.N., Henderson B.E., Le Marchand L., Haiman C.A. The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. Br J Cancer 2010, 103:120-126.
50. Wray C.M., Ziogas A., Hinojosa M.W., Le H., Stamos M.J., Zell J.A. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 2009, 52:1359-1366.
51. Luo R., Giordano S.H., Freeman J.L., Zhang D., Goodwin J.S. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist 2006, 11:1025-1033.
52. Luo R., Giordano S.H., Zhang D.D., Freeman J., Goodwin J.S. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer 2007, 109:975-982.
53. Keating N.L., Landrum M.B., Klabunde C.N., Fletcher R.H., Rogers S.O., Doucette W.R., et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity. J Clin Oncol 2008, 26:2532-2537.
54. Mols F., Beijers T., Lemmens V., van den Hurk C.J., Vreugdenhil G., van de Poll-Franse L.V. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013, 31:2699-2707.
55. Iwashyna T.J., Lamont E.B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002, 20:3992-3998.
56. Gill S., Loprinzi C.L., Sargent D.J., Thome S.D., Alberts S.R., Haller D.G., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much. J Clin Oncol 2004, 22:1797-1806.
57. Burdette-Radoux S., Muss H.B. Adjuvant chemotherapy in the elderly: whom to treat, what regimen?. Oncologist 2006, 11:234-242.
58. Gross C.P., McAvay G.J., Guo Z., Tinetti M.E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007, 109:2410-2419.
59. Caudle A.S., Kim H.J., Tepper J.E., O'Neil B.H., Lange L.A., Goldberg R.M., et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol 2008, 15:1931-1936.
60. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010, 33:931-939.
61. Davila J.A., Rabeneck L., Berger D.H., El-Serag H.B. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. Dig Dis Sci 2005, 50:1722-1728.
62. Little S.A., Jarnagin W.R., DeMatteo R.P., Blumgart L.H., Fong Y. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 2002, 6:88-94.
63. McConnell Y.J., Johnson P.M., Porter G.A. Surgical site infections following colorectal surgery in patients with diabetes: association with postoperative hyperglycemia. J Gastrointest Surg 2009, 13:508-515.
64. Vignali A., Fazio V.W., Lavery I.C., Milsom J.W., Church J.M., Hull T.L., et al. Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1014 patients. J Am Coll Surg 1997, 185:105-113.
65. 1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 2008, 53:2486-2494.
66. Hershey D.S., Given B., Given C., Corser W., Eye A.V. Predictors of diabetes self-management in older adults receiving chemotherapy. Cancer Nurs 2013.
67. Hershey D.S., Tipton J., Given B., Davis E. Perceived impact of cancer treatment on diabetes self-management. Diabetes Educ 2012, 38:779-790.
68. Pentakota S.R., Rajan M., Fincke B.G., Tseng C.L., Miller D.R., Christiansen C.L., et al. Does diabetes care differ by type of chronic comorbidity: an evaluation of the Piette and Kerr framework. Diabetes Care 2012, 35:1285-1292.
69. Piette J.D., Kerr E.A. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006, 29:725-731.
70. Garrett C.R., Hassabo H.M., Bhadkamkar N.A., Wen S., Baladandayuthapani V., Kee B.K., et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012, 106:1374-1378.
71. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
72. Lee J.H., Kim T.I., Jeon S.M., Hong S.P., Cheon J.H., Kim W.H. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2011, 131:752-759.
73. Cossor F.I., Adams-Campbell L.L., Chlebowski R.T., Gunter M.J., Johnson K., Martell R.E., et al. Diabetes, metformin use, and colorectal cancer survival in post-menopausal women. Cancer Epidemiol 2013, 37:742-749.
74. Spillane S., Bennett K., Sharp L., Barron T.I. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:1364-1373.
75. Stricker B.H., Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010, 25:245-251.
76. A phase iii randomized trial of metformin vs placebo in early stage breast cancer,. ctgov:NCT01101438.
77. http://www.clinicaltrials.gov. A trial of standard chemotherapy with metformin (vs placebo) in women with metastatic breast cancer,. ctgov:NCT01310231.